Sex differences in the temperature dependence of kidney stone presentations: a population-based aggregated case-crossover study.

Previous studies assumed a uniform relationship between heat and kidney stone presentations. Determining whether sex and other characteristics modify the temperature dependence of kidney stone presentations has implications for explaining differences in nephrolithiasis prevalence and improving projections of the effect of climate change on nephrolithiasis. We performed an aggregated case-crossover study among 132,597 children and […]

Increased infection risk in Addison’s disease and congenital adrenal hyperplasia: a primary care database cohort study.

Mortality and infection-related hospital admissions are increased in patients with primary adrenal insufficiency (PAI). However, the risk of primary care-managed infections in patients with PAI is unknown. To estimate infection risk in PAI due to Addison’s disease (AD) and congenital adrenal hyperplasia (CAH) in a primary care setting. Retrospective cohort study using UK data collected […]

Testicular volume and clinical correlates of hypothalamic-pituitary-testicular function: A cross-sectional study in obese men.

The aim of this study was to determine whether testicular volume is correlated with clinical and biochemical markers of hypothalamic-pituitary-testicular (HPT) axis function. This was a cross-sectional substudy of a larger randomized controlled trial including obese men, body mass index (BMI) ≥30 kg m-2, with a total testosterone level <12 nmol l-1. Testicular volume was […]

ESMO 2019: Primary Efficacy Analysis from the SORCE trial (RE05): Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse

Barcelona, Spain (UroToday.com) The SORCE trial is a randomized placebo-controlled trial of adjuvant sorafenib for resected high and intermediate risk (Leibovich score 3-11) renal cell carcinoma. Between July 2007 and April 2013 1,711 patients were randomized 2:3:3 to receive 3 years of 3 years of placebo, 1 year of sorafenib (400mg twice daily) followed by 2 […]

ESMO 2019: Tailored Immunotherapy Approach with Nivolumab for Advanced Renal Cell Carcinoma (TITAN-RCC)

Barcelona, Spain (UroToday.com) In pretreated metastatic renal cell carcinoma (RCC), single agent checkpoint blockade immunotherapy with the PD-1 antibody nivolumab is associated with a response rate of 25% and improvement in overall survival relative to everolimus.1 In the frontline setting, combination immunotherapy consisting of the CTLA-4 antibody ipilimumab (1 mg/kg) with nivolumab (3 mg/kg) is […]

X